SEHK:9995Biotechs
RemeGen Q1 Profit Of ¥328m Revives Bullish Narratives On Biotech Turnaround
RemeGen (SEHK:9995) opened 2026 with Q1 revenue of C¥656.2 million and basic EPS of C¥0.58, following a trailing twelve month stretch that produced total revenue of C¥3.4 billion and basic EPS of C¥2.33. The company has seen quarterly revenue move from C¥508.0 million in Q4 2024 to C¥526.0 million in Q1 2025, then to C¥656.2 million in Q1 2026. EPS shifted from a loss of C¥0.74 in Q4 2024 to a loss of C¥0.46 in Q1 2025 and then to a profit of C¥0.58 in the latest quarter, setting up a results...